Clearmind Medicine 将来の成長

Future 基準チェック /06

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clearmind Medicine.

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	54.4%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Nov 10

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Clearmind Medicine は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

CNSX:CMND - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
10/31/2023	N/A	-9	-6	-6	N/A
7/31/2023	N/A	-6	-6	-6	N/A
4/30/2023	N/A	-7	-5	-5	N/A
1/31/2023	N/A	-7	-6	-6	N/A
10/31/2022	N/A	-7	-4	-4	N/A
7/31/2022	N/A	-7	-5	-5	N/A
4/30/2022	N/A	-7	-5	-5	N/A
1/31/2022	N/A	-4	-4	-4	N/A
10/31/2021	N/A	-3	-2	-2	N/A
7/31/2021	N/A	-1	-1	-1	N/A
4/30/2021	N/A	0	-1	-1	N/A
1/31/2021	N/A	0	0	0	N/A
10/31/2020	N/A	0	0	0	N/A
7/31/2020	N/A	0	0	0	N/A
4/30/2020	N/A	0	0	0	N/A
1/31/2020	N/A	0	0	0	N/A
10/31/2019	N/A	0	0	0	N/A
7/31/2019	N/A	0	0	0	N/A
4/30/2019	N/A	0	0	0	N/A
1/31/2019	N/A	0	0	0	N/A
10/31/2018	N/A	0	0	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: Insufficient data to determine if CMND's forecast earnings growth is above the savings rate (2%).

収益対市場: Insufficient data to determine if CMND's earnings are forecast to grow faster than the Canadian market

高成長収益: Insufficient data to determine if CMND's earnings are expected to grow significantly over the next 3 years.

収益対市場: Insufficient data to determine if CMND's revenue is forecast to grow faster than the Canadian market.

高い収益成長: Insufficient data to determine if CMND's revenue is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if CMND's Return on Equity is forecast to be high in 3 years time

Clearmind Medicine 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression

Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration

Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.

Clearmind Medicine Inc. has completed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice

Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office

Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100

Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial

Clearmind Medicine Inc. Common Shares Deleted from OTC Equity

High number of new and inexperienced directors

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for Its Cocaine Addiction Treatment

Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory Board

Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as Director

Clearmind Medicine Inc. Announces CFO Changes

Clearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Clearmind Medicine Inc. and Scisparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine Inc. Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption

SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Inc. Announces the Appointment of Two New Members to Its Scientific Advisory Board

Less than half of directors are independent

Clearmind Medicine Inc. announced that it expects to receive CAD 0.96 million in funding from Medigus Ltd.

We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Clearmind Medicine Inc. announced that it has received CAD 6.225 million in funding

Clearmind Medicine Inc. announced that it expects to receive CAD 6 million in funding

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘